Award

BAK Autoactivation in Hematological Malignancies

Description: PROJECT NARRATIVE Members of the BCL2 protein family regulate life/death decisions by modulating mitochondrial outer membrane permeability. Our previous results have demonstrated that the pro-apoptotic family member BAK is constitutively activated in a subset of acute myeloid leukemia (AML) samples as well as leukemia and lymphoma cell lines, priming them to respond to certain treatments. With an eye toward improving AML therapy, this project focuses on i) understanding the cellular and biochemical bases for this constitutive BAK activation and ii) determining the implications of constitutive BAK activation for respose to AML treatment in the clinic, using as an example the response to a novel regimen of targeted agents that is currently being developed for use in AML.
Funding type: research
Funder scheme: R01
Start date: 2020-07-01
End date: 2025-06-30
Institutions: Mayo Clinic, MAYO CLINIC ROCHESTER
Funded outputs count: 7
Funder award ID: R01CA225996
OpenAlex ID: G1040924669
2026 · Annapoorna Venkatachalam, Annabella R. Strathman, et al. · Signal Transduction and Targeted Therapy
2024 · Guru Subramanian Guru Murthy, Antoine N. Saliba, et al. · Haematologica · 26
2024 · Jia Jia, Wenbo Ji, et al. · Cell Death and Differentiation · 11
2023 · Stella Victorelli, Hanna Salmonowicz, et al. · Nature · 791
2022 · Haiming Dai, Kevin L. Peterson, et al. · Cell Death and Differentiation · 19
2020 · Antoine N. Saliba, August J. John, et al. · Cancer Drug Resistance · 57